Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,946
datasets available to search
ShareScore release 0.9.0
Dataset results
5,946 results for “diabetes type 2”
Data from: Genome-wide association analysis of type 2 diabetes in the EPIC-InterAct study
<p><span><span>Type 2 diabetes (T2D) is a global public health challenge. Whilst the advent of genome-wide association studies has identified >400 genetic variants associated with T2D, our understanding of its biological mechanisms and translational insights is still limited. The EPIC-InterAct project, centred in 8 countries in the European Prospective Investigations into Cancer and Nutrition study, is one of the largest prospective studies of T2D. Established as a nested case-cohort study to investigate the interplay between genetic and lifestyle behavioural factors on the risk of T2D, a total of 12,403 individuals were identified as incident T2D cases and a representative sub-cohort of 16,154 individuals was selected from a larger cohort of 340,234 participants with a follow-up time of 3.99 million person-years. We describe the results from a genome-wide association analysis between more than 8.9 million SNPs and T2D risk among 22,326 individuals (9,978 cases and 12,348 non-cases) from the EPIC-InterAct study. The summary statistics to be shared provide a valuable resource to facilitate further investigations into the genetics of T2D. </span></span></p>
Exploratory analysis using machine learning of predictive factors for falls in persons with type 2 diabetes: A Longitudinal Study
<p>The risk of falls in elderly individuals with diabetes was reported to be 1.5 - 3 times higher than in those without diabetes. However, it is not clear what risk factors are strongly related to falls in those with diabetes. In this study, we aimed to investigate the status of falls and to identify important risk factors for falls in persons with type 2 diabetes (T2D) including the non-elderly. Participants were 316 persons with T2D who were admitted to the University of Tsukuba Hospital for treatment of diabetes. They were assessed for medical history, laboratory data and physical capabilities during the hospitalization and were given a questionnaire on falls one year after discharge. Two different statistical models, logistic regression and random forest classifier, were used to investigate important predictors of falls. The response rate to the survey was 72%; of the 226 respondents, there were 129 males and 97 females (median age 62 years). The fall rate during the first year after discharge was 19% and increased with age; fall rates were 17% for those <60 years, 20% for those aged 60 – 69 years and 24% for those ≥70 years. Logistic regression revealed that knee extension strength (β= -0.698, P = 0.002), fasting C-peptide (F-CPR) level (β= 0.492, P = 0.009) and dorsiflexion strength (β= -0.432, P = 0.047) were independent predictors of falls. The random forest classifier placed knee extension strength (covariate importance = 0.304), grip strength (0.234), F-CPR level (0.232) and dorsiflexion strength (0.230) in the top 4 important variables for falls. The rate of falls in persons with T2D was high even in middle age. Lower extremity muscle weakness as well as elevated F-CPR levels and reduced grip strength were shown to be important risk factors for falls in T2D.</p>
Effect of astragalus injection on renal tubular epithelial transdifferentiation in type 2 diabetic mice
<p><strong>Background</strong>: Astragalus injection is used by practitioners of traditional Chinese medicine to treat diabetic nephropathy (DN). The current study was conducted to determine the effect of astragalus on tubular epithelial transdifferentiation during the progression of DN in KKAy mice, as well as to investigate the molecular mechanism underlying this effect.</p> <p> </p> <p><strong>Methods: </strong>Diabetic, 14-week-old, male KKAy mice were randomly divided into a model group and an astragalus treatment group, while age-matched male C57BL/6J mice were selected as controls. The treatment group received daily intraperitoneal injections of astragalus (0.03 mL/10 g per day), while the model group received injections of an equal volume of saline. Mice were euthanized after 24 weeks. Serum samples were obtained from the animals in each group for blood glucose measurement. Kidney tissue samples were used for morphometric studies. The mRNA and protein expression levels of transforming growth factor beta 1 (TGF-β1), transforming growth factor beta receptor 1 (TGFβ-R1), alpha smooth muscle actin (α-SMA), and E-cadherin were evaluated using real-time polymerase chain reaction (PCR) and western blotting.</p> <p> </p> <p><strong>Results: </strong>Astragalus significantly reduced blood glucose levels; inhibited morphological changes in the kidneys of KKAy mice; reduced mRNA and protein expression levels of TGF-β1, TGFβ-R1, and α-SMA; and increased E-cadherin expression.</p> <p> </p> <p><strong>Conclusions:</strong> Tubular epithelial transdifferentiation plays an important role in the development of DN in diabetic mice. Administration of astragalus likely prevents or mitigates DN by suppressing tubular epithelial transdifferentiation, protecting KKAy mice from renal damage.</p>
Hypermethylation of HOOK2 gene and its relation with Type 2 diabetes susceptibility in individuals with obesity
<p>Failure in glucose response to insulin is a common pathology associated with obesity. In this study, we analyzed the genome wide DNA methylation profile of visceral adipose tissue samples in a population of individuals with obesity and assessed whether differential methylation profiles are associated with the presence of type 2 diabetes (T2D).</p> <p>More than 485,000 CpG genome sites from visceral adipose tissue samples from women with obesity undergoing gastric bypass (n=18), and classified as suffering from type 2 diabetes or not (no type 2 diabetes, NT2D), were analyzed using DNA methylation arrays.</p>
Multiplexed imaging analysis of human pancreatic islets from donors with and without type 2 diabetes
<p>This record contains tabular data from traditional and multiplexed immunohistochemistry experiments presented in the manuscript <i>Genetic risk converges on regulatory networks mediating early type 2 diabetes</i> (<a href="https://doi.org/10.1038/s41586-023-06693-2">Walker, Saunders & Rai et al., <i>Nature</i> 2023</a>), a body of work that includes tissue imaging, <a href="https://theparkerlab.shinyapps.io/Islet-RNAseq-WGCNA/">sorted islet cell transcriptomics</a>, and islet functional analysis of donors with early-stage type 2 diabetes (T2D) and control donors. Images can be viewed interactively on Pancreatlas (RRID:SCR_018567): <a href="https://pancreatlas.org/datasets/904/explore">https://pancreatlas.org/datasets/904/explore</a>.</p><p>All immunohistochemistry was performed on lightly PFA-fixed human pancreatic tissue (sample characteristics available in Supplementary Table 1). For traditional immunohistochemistry, islets were imaged at 20× with 2× digital zoom using a FV3000 confocal laser scanning microscope (Olympus) or full cross-sections were scanned on a ScanScope FL (Leica/Aperio). Quantitative analysis was carried out using HALO™ (Indica Labs) or Metamorph (Molecular Devices) software. For multiplexed immunohistochemistry, images were acquired using the PhenoCycler (CODEX) Open system (Akoya Biosciences) integrated with a BZ-X810 epifluorescence microscope (Keyence) with a CFI plan Apo I 20x/0.75 objective (Nikon). Image alignment, stitching, background subtraction, and deconvolution were performed using the CODEX Processor v1.7.0.6 (Akoya Biosciences). Cell segmentation and cell type annotations were generated using the HALO HighPlex FL v3.2.1 module (Indica Labs). For cell neighborhood (CN) analysis, two methods were applied in parallel to CODEX data from annotated islets: a community detection method, termed <i>Dynamic CF-IDF</i>, and a <i>k</i>-means approach. Packages used for cell neighborhood analyses are published in <a href="http://github.com/liu-bioinfo-lab/Cellular-Neighborhood-Analysis">Github</a>.</p>
Supplementary data for manuscript "Genetic risk converges on regulatory networks mediating early type 2 diabetes"
<p>Supplementary data for manuscript "Genetic risk converges on regulatory networks mediating early type 2 diabetes" Nature 624, 621–629 (2023). <a href="https://doi.org/10.1038/s41586-023-06693-2">https://doi.org/10.1038/s41586-023-06693-2</a></p> <p>Brief description of the included files is given below. Please visit the manuscript website for latest updates: <a href="http://theparkerlab.org/manuscripts/2021_islet-rfx6/">http://theparkerlab.org/manuscripts/2021_islet-rfx6/</a></p>
Difference between finger prints of type 2 diabetics and healthy individuals
<p>This dataset provides the fingerprint patterns of type 2 diabetic and non-diabetic patients. Careful inclusion and exclusion criteria were used to select participants so that their fingerprints could be compared for research purposes.</p>
Evaluation of comparative efficacy of Babool Vati versus Tablet Metformin in the Management of Type 2 Diabetes Mellitus (Prameha)- a randomized controlled trial protocol
Open the record for dataset details and reuse information.
GCK variants and their annotations for "Underestimated risk of secondary complications in pathogenic and glucose-elevating GCK variant carriers with type 2 diabetes"
<p>This file provides annoatations for GCK variants as dsecribed in "Underestimated risk of secondary complications in pathogenic and glucose-elevating GCK variant carriers with type 2 diabetes"</p>
Medicinal properties of Morus alba for the control of type 2 diabetes mellitus: a systematic review
<p><strong>Background:</strong> the objective of this review was to evaluate the medicinal potential of <em>Morus alba</em> leaves on the control of Type 2 Diabetes Mellitus (DM2). Research question: what is the medicinal potential of <em>Morus alba</em> leaves in the control of DM2? <strong>Methods:</strong> It was based on the PRISMA Declaration. The included studies were extracted from Scopus, Pubmed, ScienceDirect, Scielo, and Google Scholar; January 2015 to July 2021, Key search terms were MeSH and DeCS: <em>Morus alba</em>, mulberry, hypoglycemic agent. The inclusion criteria were: studies in rats administered <em>Morus alba</em> leaf extracts; studies that included the dimensions of lipidemia and glycemia; studies that included indicators such as fasting glucose, postprandial glucose, glycosylated hemoglobin, triglycerides, low-density lipoproteins, total cholesterol, and insulin resistance. Exclusion criteria: studies in which <em>Morus alba</em> leaves were administered with other plants; studies with other parts of the <em>Morus alba</em> plant; proteomic studies, cancer, duplicate studies, in vitro studies, and evaluation of included studies. All included investigations were evaluated for biases. <strong>Results:</strong> The extracts of <em>Morus alba</em> leaves at the phytochemical level improve glucose uptake. Chlorogenic acid, isoquercitrin, and quercitrin, present in the leaves of <em>Morus alba</em> have hypoglycemic properties and an ameliorating effect on diabetic nephropathy. This leaf has pharmacological effects such as glucose absorption, insulin secretion production, antioxidant and anti-inflammatory agent, antihyperglycemic and antihyperlipidemic activities, and obesity management. <strong>Conclusions:</strong> <em>Morus alba</em> leaves have pharmacological effects on DM2 that include glucose absorption, production of insulin secretion, antioxidant agent, antihyperglycemic and antihyperlipidemic activities, and obesity control. Beyond these results, there is a lack of studies on the potential and synergistic effects of the components of <em>Morus alba</em> leaves, which limit the possibility of a more effective therapy using the leaves of the plant.</p>
Blood glucose modulation and safety of efferent vagus nerve stimulation in a type 2 diabetic rat model
<p class="MsoNormal"><span>Vagus nerve stimulation is emerging as a promising treatment for type 2 diabetes. Here, we evaluated the ability of stimulation of the vagus nerve to reduce glycaemia in awake, freely moving metabolically compromised rats. A model of type 2 diabetes (n=10) was induced using a high-fat diet and low doses of streptozotocin. Stimulation of the abdominal vagus nerve was achieved by pairing 15 Hz pulses on a distal pair of electrodes </span><span>with high-frequency blocking stimulation (26 kHz, 4 mA) on a proximal pair of electrodes to preferentially produce efferent conducting activity </span><span>(eVNS)</span><span>. </span><span>Stimulation was well tolerated in awake, freely moving rats. During 1 hour of eVNS, glycaemia decreased in 90% of subjects (-1.25±1.25 mM·h, <em>P</em>=0.017), and 2 dB above neural threshold was established as the most effective 'dose' of eVNS (<em>P</em>=0.009). Following 5 weeks of implantation, eVNS was still effective, resulting in significantly decreased glycaemia (-1.7±0.6 mM·h, <em>P</em>=0.003) during 1 hour of eVNS. There were no overt changes in fascicle area or signs of histopathological damage observed in implanted vagal nerve tissue following chronic implantation and stimulation. </span><span>Demonstration of the biocompatability and safety of eVNS in awake, </span><span>metabolically compromised</span><span> animals is a critical first step to establishing this therapy for clinical use. With further development, </span><span>eVNS could be a promising novel therapy for treating type 2 diabetes.</span></p>
The efficacy and safety of meal replacement in patients with type 2 diabetes: a systematic review and meta-analysis
<p>There are supplemental materials for a systematic review and meta-analysis, which studied the efficacy and safety of meal replacement in patients with type 2 diabetes, with a focus on subgroup analysis of variable participant characteristics and MR prescription.</p>
Data sets from "How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials"
<p>The two data sets (in CSV format) contain the complete infomation to reproduce the analyses from the paper "How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials" which will be published in Diabetologia.</p> <p>The data set "Data_LogSD.csv" contains the data for the primary analysis of the Log(SD) as given in the main paper, the data set "Data_LogSD_BL_CORR.csv" contains the data for the analysis of the baseline-corrected Log(SD) as given in the electronic supplementary material.</p>
Prospective cohort study of a community-based primary care program's effects on pharmacotherapy quality in low-income Peruvians with type 2 diabetes and hypertension
<p>A door-to-door survey was conducted to enumerate all household members by age and sex in a low-income community in Peru. 856 adults 35 years and older were eligible to participate in screening for type 2 diabetes and hypertension. 709 (83%) participated in screening. 130 (18.3%) were diagnosed with hypertension and/or type 2 diabetes of which 109 (84%) participated at program onset and 22 were added later from earlier non-participants in screening or program onset to form the cohort of 131 patients with diabetes and/or hypertension. The primary care program had components of the Chronic Care Model, community health workers, and freely accessible visits and medications. The program operated between September 2011 and May 2014, and consisted of two care periods (separated by a six-month hiatus), first a 10-month home-care period, then a 17-month clinic-care period. The dataset is two files corresponding to two exposures: the 27-month program overall (post- versus pre-) (N=262 observations, 131 pairs with patients as self-controls) and care period (clinic versus home), N=211 (109 home and 102 clinic observations, >131 because 80 patients participated in both care periods). Exposures were evaluated for their effects on guidelines-based pharmacotherapy standards: hypoglycemic and antihypertensive medications, low-dose aspirin, and first-line angiotensin converting enzyme inhibitor (ACEi) treatment of diabetes with elevated blood pressure.</p>
Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT01276288. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Insulin Schemes for Type 2 Diabetes Control
ClinicalTrials.gov study NCT03350984. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
ClinicalTrials.gov study NCT00900146. IPD Sharing: Not stated. Countries: 14. Publications: 3.
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
ClinicalTrials.gov study NCT02649465. IPD Sharing: NO. Countries: 1. Publications: 2.
Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
ClinicalTrials.gov study NCT01549964. IPD Sharing: Not stated. Countries: 11. Publications: 1.
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT00622284. IPD Sharing: Not stated. Countries: 16. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.